Cargando…

Cancer 3D Models for Metallodrug Preclinical Testing

Despite being standard tools in research, the application of cellular and animal models in drug development is hindered by several limitations, such as limited translational significance, animal ethics, and inter-species physiological differences. In this regard, 3D cellular models can be presented...

Descripción completa

Detalles Bibliográficos
Autores principales: Engrácia, Diogo M., Pinto, Catarina I. G., Mendes, Filipa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418685/
https://www.ncbi.nlm.nih.gov/pubmed/37569291
http://dx.doi.org/10.3390/ijms241511915
_version_ 1785088324552097792
author Engrácia, Diogo M.
Pinto, Catarina I. G.
Mendes, Filipa
author_facet Engrácia, Diogo M.
Pinto, Catarina I. G.
Mendes, Filipa
author_sort Engrácia, Diogo M.
collection PubMed
description Despite being standard tools in research, the application of cellular and animal models in drug development is hindered by several limitations, such as limited translational significance, animal ethics, and inter-species physiological differences. In this regard, 3D cellular models can be presented as a step forward in biomedical research, allowing for mimicking tissue complexity more accurately than traditional 2D models, while also contributing to reducing the use of animal models. In cancer research, 3D models have the potential to replicate the tumor microenvironment, which is a key modulator of cancer cell behavior and drug response. These features make cancer 3D models prime tools for the preclinical study of anti-tumoral drugs, especially considering that there is still a need to develop effective anti-cancer drugs with high selectivity, minimal toxicity, and reduced side effects. Metallodrugs, especially transition-metal-based complexes, have been extensively studied for their therapeutic potential in cancer therapy due to their distinctive properties; however, despite the benefits of 3D models, their application in metallodrug testing is currently limited. Thus, this article reviews some of the most common types of 3D models in cancer research, as well as the application of 3D models in metallodrug preclinical studies.
format Online
Article
Text
id pubmed-10418685
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104186852023-08-12 Cancer 3D Models for Metallodrug Preclinical Testing Engrácia, Diogo M. Pinto, Catarina I. G. Mendes, Filipa Int J Mol Sci Review Despite being standard tools in research, the application of cellular and animal models in drug development is hindered by several limitations, such as limited translational significance, animal ethics, and inter-species physiological differences. In this regard, 3D cellular models can be presented as a step forward in biomedical research, allowing for mimicking tissue complexity more accurately than traditional 2D models, while also contributing to reducing the use of animal models. In cancer research, 3D models have the potential to replicate the tumor microenvironment, which is a key modulator of cancer cell behavior and drug response. These features make cancer 3D models prime tools for the preclinical study of anti-tumoral drugs, especially considering that there is still a need to develop effective anti-cancer drugs with high selectivity, minimal toxicity, and reduced side effects. Metallodrugs, especially transition-metal-based complexes, have been extensively studied for their therapeutic potential in cancer therapy due to their distinctive properties; however, despite the benefits of 3D models, their application in metallodrug testing is currently limited. Thus, this article reviews some of the most common types of 3D models in cancer research, as well as the application of 3D models in metallodrug preclinical studies. MDPI 2023-07-25 /pmc/articles/PMC10418685/ /pubmed/37569291 http://dx.doi.org/10.3390/ijms241511915 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Engrácia, Diogo M.
Pinto, Catarina I. G.
Mendes, Filipa
Cancer 3D Models for Metallodrug Preclinical Testing
title Cancer 3D Models for Metallodrug Preclinical Testing
title_full Cancer 3D Models for Metallodrug Preclinical Testing
title_fullStr Cancer 3D Models for Metallodrug Preclinical Testing
title_full_unstemmed Cancer 3D Models for Metallodrug Preclinical Testing
title_short Cancer 3D Models for Metallodrug Preclinical Testing
title_sort cancer 3d models for metallodrug preclinical testing
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418685/
https://www.ncbi.nlm.nih.gov/pubmed/37569291
http://dx.doi.org/10.3390/ijms241511915
work_keys_str_mv AT engraciadiogom cancer3dmodelsformetallodrugpreclinicaltesting
AT pintocatarinaig cancer3dmodelsformetallodrugpreclinicaltesting
AT mendesfilipa cancer3dmodelsformetallodrugpreclinicaltesting